Skip to main content

Editor's Note: Green and red arrows refer to intraday stock price movement.

NEW YORK (

TheStreet

) --

CHANGE IN RATINGS

Arris Group

(ARRS)

rated new Neutral at Credit Suisse. $10 price target. Company will likely see muted growth, relative to its peers.

Bed Bath & Beyond

(BBBY)

rated new Neutral at Robert Baird. $48 price target. Company is a best-of-breed retailer, but margins already appear to be at peak levels.

Crown Holdings

(CCK)

downgraded at Keybanc from Buy to Hold. Valuation call.

Dollar Tree

(DLTR)

Scroll to Continue

TheStreet Recommends

downgraded at Barclays to Equal-weight. $53 price target. Market is already pricing in a strong earnings report next week.

Clearwire

(CLWR)

upgraded at BofA/Merrill from Underperform to Neutral. $7.50 price target. Funding risks are priced into the stock, and Sprint is not likely to walk away from the company.

Eaton

(ETN)

upgraded at Goldman from Neutral to Buy. $117 price target. Stock was also added to the Conviction List. Estimates increased, as the company has strong operating momentum.

Genworth Financial

(GNW)

downgraded at Morgan Stanley from Overweight to Equal-weight. Estimates also reduced through 2011.

Gen-Probe

(GPRO)

upgraded at Piper from Neutral to Overweight. $58 price target. Office visit trends are improving.

Hologic

(HOLX)

upgraded at Piper from Neutral to Overweight. $22 price target. Company has multiple potential catalysts.

Starwood Hotels

(HOT)

rated new Neutral at Janney Montgomery. $55 price target. Stock is already pricing in a global sales recovery.

JDS Uniphase

(JDSU)

rated new Neutral at Credit Suisse. $12 price target. Diversified business model could limit the company's growth and margin potential.

LDK Solar

(LDK)

upgraded at Argus from Hold to Buy, Argus Research said. $17 price target. Company is seeing higher demand.

Lorillard

(LO)

downgraded at Citigroup to Hold. $95 price target. Potential menthol regulations continue to hang over the stock.

MetLife

(MET)

downgraded at Morgan Stanley from Overweight to Equal-weight. Domestic growth headwinds remain.

Altria

(MO)

downgraded at Citigroup to Hold. Valuation call, based on a $27 price target.

Mastec

(MTZ)

downgraded at Morgan Stanley from Overweight to Equal-weight. Valuation call, based on a $17 price target.

Mylan

(MYL)

rated new Overweight at Morgan Stanley. $25 price target. Company should continue to expand its margins over the next several quarters.

Noble Energy

(NBL)

downgraded at Morgan Stanley from Overweight to Equal-weight. Company likely will not see above-average growth until 2012.

Nvidia

(NVDA)

upgraded at Needham from Hold to Buy. $16 price target. Company should regain GPU market share and see Tegra ramp in 2011.

Nvidia

(NVDA)

estimates, target boosted at Citigroup. Shares of NVDA now seen reaching $17. Estimates also upped, to match the company's new guidance. Buy rating.

Teva Pharmaceuticals

(TEVA)

rated new Equal-weight at Morgan Stanley. Copaxone will face generics threats.

UnitedHealth

(UNH)

rated new Hold at Jefferies. $40 price target. Company is gaining market share, but faces pricing pressure.

Ultra Petroleum

undefined

rated new Hold at Citigroup. Coverage of UPL was initiated with a Hold rating. $50 price target. Rockies growth could slow in the new year.

Valspar

(VAL)

downgraded at JP Morgan from Overweight to Neutral. $33 price target. Company may find it more difficult to pass along higher input costs to customers.

Wellpoint

(WLP)

rated new Buy at Jefferies. $69 price target. Company delivers steady returns. Management is likely to buyback stock and add a dividend.

Waste Management

(WM)

rated new Outperform at William Blair. Company can deliver industry-high growth.

Williams-Sonoma

(WSM)

rated new Outperform at Robert Baird. $42 price target. Company is leveraged to secular growth trends in e-commerce and can expand its margins.

This article was written by a staff member of TheStreet.